News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
Fewer foot ulcers on GLP-1 drugs, and nearly twice the Charcot risk
Read more: Fewer foot ulcers on GLP-1 drugs, and nearly twice the Charcot riskFor people with type 2 diabetes who already have nerve damage in their feet, a matched comparison of 39,540 US patients found fewer foot ulcers on GLP-1 receptor agonists than on DPP-4 inhibitors — and nearly twice the rate of Charcot neuroarthropathy, a joint-destroying complication of the foot. Amputation and bone-infection rates were the same…
-
Trials logged malnutrition in 0.12% of patients. Bloodwork flagged 2.9%
Read more: Trials logged malnutrition in 0.12% of patients. Bloodwork flagged 2.9%A meta-analysis of 19 randomised trials behind semaglutide, tirzepatide and liraglutide reports a gap between what those trials recorded and what their own bloodwork showed. Investigators logged malnutrition as an adverse event in 0.12% of participants. Laboratory screening in the same trials found abnormally low lymphocyte counts in 2.90% of people taking active drug, against…
-
GLP-1 drugs cut sleep apnea, but a new review says they do not replace CPAP
Read more: GLP-1 drugs cut sleep apnea, but a new review says they do not replace CPAPA review in JAMA Otolaryngology–Head & Neck Surgery has pulled together what is known about GLP-1 drugs and obstructive sleep apnea, and its bottom line is a qualified one: the drugs work, and they work less well than CPAP. Across six meta-analyses the reduction in the apnea-hypopnea index ran from 5.7 to 21.9 events per…
-
Surgery beat GLP-1 drugs on heart outcomes in a 932,000-patient review
Read more: Surgery beat GLP-1 drugs on heart outcomes in a 932,000-patient reviewA network meta-analysis published in Endocrinology, Diabetes & Metabolism pooled 43 studies covering 932,380 patients and compared bariatric surgery against GLP-1 receptor agonists on hard cardiovascular outcomes. Surgery was associated with reductions in major adverse cardiovascular events, heart failure and myocardial infarction. The drugs were associated with a reduction in major adverse cardiovascular events but…
-
GLP-1 drugs and optic-nerve injury: 29 cases, and an interval that crosses 1
Read more: GLP-1 drugs and optic-nerve injury: 29 cases, and an interval that crosses 1A study published this month in Ophthalmology Retina looked for a link between GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy, a sudden and usually permanent loss of vision in one eye. Across 19,505 adults with type 2 diabetes it found 29 cases in total, and could not rule out either a real effect or…
-
Metformin plus a GLP-1: the acidosis a normal glucose can hide
Read more: Metformin plus a GLP-1: the acidosis a normal glucose can hideMetformin and a GLP-1 receptor agonist are one of the most common drug pairings in type 2 diabetes. A case report and literature review published in Kidney360 describes what happens when that combination goes wrong: a 59-year-old woman developed severe metformin-associated lactic acidosis alongside ketoacidosis, while her blood glucose stayed close to normal — the…
-
Reflux is reported two to five times more often on GLP-1 drugs, in three countries
Read more: Reflux is reported two to five times more often on GLP-1 drugs, in three countriesA pharmacovigilance study published online in Gut and Liver on 2 September pooled the national adverse-event databases of the United States, Japan and Canada and found gastroesophageal reflux disease reported roughly two to five times more often for GLP-1 drugs than for a comparator diabetes drug class. The signal held in all three countries. It…
-
GLP-1 prescribing to children aged 8 to 11 is up sharply and still rare
Read more: GLP-1 prescribing to children aged 8 to 11 is up sharply and still rareA research brief published in Pediatrics on 4 September finds that GLP-1 prescribing to children aged 8 to 11 with obesity rose steeply between 2019 and 2026 while remaining uncommon: across 3,520,531 children in the dataset, 0.6% received a prescription. Every one of those prescriptions was off-label. The three drugs counted are labelled from age…
-
Higher semaglutide doses tracked with fewer neuropsychiatric events, not more
Read more: Higher semaglutide doses tracked with fewer neuropsychiatric events, not moreA study of 63,215 patients with pre-existing neuropsychiatric conditions, published on 1 September, found semaglutide associated with broadly lower rates of neuropsychiatric events over two years than metformin, SGLT2 inhibitors or DPP-4 inhibitors. Within the semaglutide group, patients who reached higher doses had fewer such events afterwards — the inverse of the dose-toxicity pattern implied…
-
Semaglutide slowed ageing and extended lifespan in old female mice
Read more: Semaglutide slowed ageing and extended lifespan in old female miceA study published in Nature on 2 September reports that semaglutide, started late in life, slowed several measures of ageing in mice and extended how long they lived. The comparison arm was calorie restriction — the one intervention that has reliably stretched rodent lifespan for the better part of a century — and semaglutide matched…